AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01058863 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhaler
Description: Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.
Study NCT01058863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inhaler
Description: Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.
Study NCT02254850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flow Mediated Dilation
Description: Patients performed FMD by an high-resolution ultrasound linear probe in a supine decubitus and conditioned room.The probe was placed on humeral artery and connected to a mechanically arm. Then were performed several measurement s of the internal diameter of the vessel (edge to edge distance), on the R wave of the ECG, and software calculated the average value.The post-ischemic vasodilation was induced using a sphygmomanometer placed on the forearm, distal to the elbow crease, kept inflated to 250 mmHg for 5 minutes. The flow rate was recorded immediately after the desufflation; the diameter of the brachial artery was measured several times after desufflation (for 60-90 seconds). Nextly, the FMD was calculated as the percentage difference between the maximum diameter of the post-ischemic reached and the mean diameter of the vessel.
Study NCT02254850 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Flow Mediated Dilation
Description: Patients performed FMD by an high-resolution ultrasound linear probe in a supine decubitus and conditioned room.The probe was placed on humeral artery and connected to a mechanically arm. Then were performed several measurement s of the internal diameter of the vessel (edge to edge distance), on the R wave of the ECG, and software calculated the average value.The post-ischemic vasodilation was induced using a sphygmomanometer placed on the forearm, distal to the elbow crease, kept inflated to 250 mmHg for 5 minutes. The flow rate was recorded immediately after the desufflation; the diameter of the brachial artery was measured several times after desufflation (for 60-90 seconds). Nextly, the FMD was calculated as the percentage difference between the maximum diameter of the post-ischemic reached and the mean diameter of the vessel.
Study NCT02254850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesoglycan
Description: The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml.
Study NCT02254850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesoglycan
Description: The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg.
Study NCT02254850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
Study NCT03451799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: A 4-month ketogenic diet will be supervised and monitored by the study investigators. Study dietitians will create personalized meal plans for each patient with the goal of achieving and maintaining metabolic ketosis.
Study NCT02254850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
Study NCT03653416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ipack
Description: IPACK block - local anesthesia injected safely under ultrasound guidance in the interspace between the popliteal artery and capsule of the knee.
Study NCT03653416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20 cc of bupivacaine(o.25%) injection
Study NCT03653416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peri Articular Infiltration
Description: Adductor Canal Catheter and Peri Articular Infiltration
Study NCT03451799 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard-of-care radiation
Description: Patients will receive standard-of-care radiation. Radiation is not protocol directed.
Study NCT03451799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-care Temozolomide
Description: Patients will receive standard-of-care temozolomide. Temozolomide is not protocol directed.
Study NCT00746395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: 24 mcg oral administration
Study NCT00746395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT03653416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri Articular Infiltration
Description: Adductor Canal Catheter and Peri Articular Infiltration
Study NCT00715507 — intervention group
Intervention type: DEVICE
Intervention: medication monitor
Description: the medication monitor will aid in expertise and decision-making.
Study NCT00416923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00658736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Injection of bupivacaine and triamcinolone
Study NCT00658736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivicaine alone
Description: Injection of bupivacaine
Study NCT03859336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transdermal Neuromodulation Stimulation
Description: The TEN device administers a tuned high frequency electrical stimulation delivered to the cervical plexus (C2-C4) on the back of the neck for 20 minutes. This stimulation will activate common trigeminovagal pathways modulating noradrenergic signaling to attenuate sympathetic activity. This stimulation can subsequently regulate the activity of several deep-brain nuclei within the ascending reticular activating system (RAS). Nuclei in the RAS regulate powerful neuromodulators like norepinephrine (NE), acetylcholine (ACh), and serotonin (5-HT). The investigators will examine whether this modulation from TENS will decrease anxiety and improve sleep quality in the study participants.
Study NCT01902589 — intervention group
Intervention type: OTHER
Intervention: Helicobacter Pylori Culture
Description: Biopsy specimens for histology will be fixed in formalin, embedded in paraffin and sectioned and stained with hematoxylin and eosin.~The microbiological workup will include an imprint of the biopsy on a slide followed by a gram stain for the purpose of demonstrating H. pylori in situ. Further the biopsies will be streaked out on chocolate agar, Sheep blood agar and H. pylori selective agar supplemented with Polymixin to suppress possible contaminants.~4 days of incubation in a micro aerophilic atmosphere will follow . Susceptibility testing of H pylori will be performed with E test on Mueller Hinton agar supplemented with defibrinated sheep blood using a MacFalrland 3.0 density of a bacterial suspension. Reading the susceptibility will take place following 72 hours of incubation in a micro aerophilic atmosphere.
Study NCT04616326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SQ
Study NCT04616326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ
Study NCT04432012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate 4 mg/ml intravenous
Description: Perioperative intravenous injection of 3 ml of solution (9mg of dexamethasone)
Study NCT04432012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate 4 mg/ml intra-articular
Description: Perioperative intra-articular injection of 3 ml of solution (9mg of dexamethasone)
Study NCT03742089 — intervention group
Intervention type: DEVICE
Intervention: Bone Anchored Hearing Surgery
Description: This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected will be used to assess the implant stability development of the Ponto BHX implant during up to 24 months after implantation in a pediatric population undergoing BAHS. The study will also monitor the Ponto BHX implant safety and survival throughout the study period.
Study NCT03562832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP inhibitor 2X-121
Description: 600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
Study NCT02446600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02446600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT02446600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO
Study NCT02446600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02446600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02446600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT02446600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT02446600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV
Study NCT02446600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02446600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02446600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02446600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02446600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02446600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT02446600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT02446600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT02446600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT02446600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT02446600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02446600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02446600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03995628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: One dose of dexamethasone (0.5 mg/kg) on post-operative day 3 after tonsillectomy
Study NCT03995628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo on post-operative day 3 after tonsillectomy
Study NCT03983278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School Model
Description: Free delivery of glasses at the school within two weeks after screening
Study NCT03983278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral Model
Description: After the primary screening children referred to nearby Vision Center/ secondary center for refraction and delivery of free glasses.
Study NCT03983278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral Model + Cost Recovery
Description: After the screening children referred to Vision Center for refraction and delivery of free glasses with the option to purchase upgrade glasses
Study NCT02810197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychopathological assessment
Study NCT02810197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Study NCT02810197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI)
Study NCT02718326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection [IAI]
Study NCT01739595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule taken one time daily for 3 months
Study NCT02001012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination
Study NCT02001012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Study NCT02255630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling Exercise
Study NCT00101569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).
Study NCT00101569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21).
Study NCT03729349 — intervention group
Intervention type: BIOLOGICAL
Intervention: Golimumab
Description: Participants will receive golimumab as a part of clinical practice.
Study NCT00788255 — intervention group
Intervention type: DRUG
Intervention: Final exogenous oxytocin concentration=22.5 μU/mL
Description: Citrated whole blood 1mL + 23μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
Study NCT02718326 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Study NCT00788255 — intervention group
Intervention type: DRUG
Intervention: Final exogenous oxytocin concentration=30.1μU/mL
Description: Citrated whole blood 1mL + 31μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
Study NCT00788255 — intervention group
Intervention type: DRUG
Intervention: Final exogenous oxytocin concentration=32.9μU/mL
Description: Citrated whole blood 1mL + 34μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
Study NCT02742506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: EEG will be performed to assess brain activity in response to sounds of different nature, including music and the given name of the registered person
Study NCT02742506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalography (EEG)
Description: EEG will be performed to assess brain activity in response to sounds of different nature, including music and the given name of the registered person
Study NCT03509922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anplag Tab. 100mg bid
Description: sarpogrelate hydrochloride 100mg bid for 24 weeks
Study NCT03509922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anplag Tab. 100mg tid
Description: sarpogrelate hydrochloride 100mg tid for 24 weeks
Study NCT00972179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous or intravenous injection.
Study NCT00972179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Administered by subcutaneous or intravenous injection
Study NCT01878565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug
Description: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20 μg of HBV vaccine subcutaneously at day 6.
Study NCT01878565 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF control
Description: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with saline placebo intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
Study NCT05671900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg, Docetaxel 37.5g
Description: 6 weekly instillations of gemcitabine (1 gram of gemcitabine in 50 ml of sterile water) followed immediately by docetaxel (37.5 mg of docetaxel in 50 mL of saline) and subsequent monthly maintenance installations for those with no evidence of disease.
Study NCT02211157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat breakfast
Study NCT00308282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
Study NCT01538615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOME Plus intervention
Description: The HOME Plus program families will participate in monthly, two-hour group sessions for ten months at local community centers. Each session offers new ideas focusing on family meals, healthy eating, and reducing sedentary behavior. At each session, families prepare and eat a meal together and participate in small group discussions and activities for both parent and child groups to promote healthy behaviors in the home. Topics include planning healthy meals and snacks with your family, having meals with your family more often, and improving the healthfulness of the food available at home. Families also receive periodic supportive phone calls throughout the year using motivational interviewing techniques to promote healthy behaviors to prevent and reduce childhood obesity.
Study NCT02212938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 14332 CL
Study NCT01343004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0 mcg subcutaneous daily
Study NCT02212938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat breakfast
Study NCT04193293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Phosphoinositide 3-kinase (PI3K) Inhibitor
Study NCT04193293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immunotherapy (programmed cell death protein 1 \[PD-1\] inhibitor)
Study NCT01343004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA058 80 mcg
Description: BA058 80 mcg subcutaneous daily
Study NCT01343004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide
Description: teriparatide 20 mcg subcutaneous daily
Study NCT03024086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1252
Description: DWJ1252 and Placebo of Gasmotin
Study NCT03024086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gasmotin
Description: Gasmotin and Placebo of DWJ1252
Study NCT00910221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin tablet
Study NCT00910221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT04112823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Description: Dexamethasone 4mg + metoclopramide 10mg, intravenously
Study NCT04112823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 16mg
Description: Dexamethasone 16mg + metoclopramide 10mg, intravenously
Study NCT00772603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active tablet identical to study drug tablets
Study NCT00772603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2400mg SPN-804
Description: tablets containing 600mg OXC XR, identical to non-active tablets
Study NCT00772603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1200mg SPN-804
Description: two active tablets and two non-active tablets, all identical
Study NCT00089011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00089011 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo radiotherapy
Study NCT00089011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given IV or PO
Study NCT00089011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO